261 related articles for article (PubMed ID: 34493145)
21. Αlpha-thalassemia: A practical overview.
Musallam KM; Cappellini MD; Coates TD; Kuo KHM; Al-Samkari H; Sheth S; Viprakasit V; Taher AT
Blood Rev; 2024 Mar; 64():101165. PubMed ID: 38182489
[TBL] [Abstract][Full Text] [Related]
22. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
23. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
[TBL] [Abstract][Full Text] [Related]
24. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
25. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.
Porter J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):361-370. PubMed ID: 30504333
[TBL] [Abstract][Full Text] [Related]
26. Iron chelation therapy in the management of thalassemia: the Asian perspectives.
Viprakasit V; Lee-Lee C; Chong QT; Lin KH; Khuhapinant A
Int J Hematol; 2009 Nov; 90(4):435-445. PubMed ID: 19862602
[TBL] [Abstract][Full Text] [Related]
27. Can N-acetylcysteine reduce red blood cell transfusion burden in patients with transfusion-dependent β-thalassemia?
Bahoush G; Rahab M; Ahmadvand P
Pediatr Hematol Oncol; 2024 May; 41(4):251-259. PubMed ID: 38088332
[TBL] [Abstract][Full Text] [Related]
28. Recent perspectives of pediatric β-thalassemia.
An Q; Fan C; Xu S
Minerva Pediatr (Torino); 2022 Jun; 74(3):365-372. PubMed ID: 29479942
[TBL] [Abstract][Full Text] [Related]
29. Challenges of blood transfusions in β-thalassemia.
Shah FT; Sayani F; Trompeter S; Drasar E; Piga A
Blood Rev; 2019 Sep; 37():100588. PubMed ID: 31324412
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review.
Dighriri IM; Alrabghi KK; Sulaiman DM; Alruwaili AM; Alanazi NS; Al-Sadiq AA; Hadadi AM; Sahli BY; Qasem BA; Alotaibi MT; Asiri TT; Majrashi SM; Alotibia NT; Alhamyani AT; Alharbi AA
Cureus; 2022 Nov; 14(11):e31570. PubMed ID: 36540460
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life with standard and curative therapies in thalassemia: A narrative literature review.
Shah R; Badawy SM
Ann N Y Acad Sci; 2024 Feb; 1532(1):50-62. PubMed ID: 38270933
[TBL] [Abstract][Full Text] [Related]
32. Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.
Darvishi-Khezri H; Karami H
Adv Ther; 2021 Apr; 38(4):1732-1745. PubMed ID: 33661441
[TBL] [Abstract][Full Text] [Related]
33. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
34. Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia.
Sheth S; Taher AT; Coates TD; Kattamis A; Cappellini MD
Br J Haematol; 2023 Jun; 201(5):824-831. PubMed ID: 37037668
[TBL] [Abstract][Full Text] [Related]
35. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.
Ballas SK; Zeidan AM; Duong VH; DeVeaux M; Heeney MM
Am J Hematol; 2018 Jul; 93(7):943-952. PubMed ID: 29635754
[TBL] [Abstract][Full Text] [Related]
36. Clinical Management of Patients With Thalassemia Syndromes.
Martin M; Haines D
Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
[TBL] [Abstract][Full Text] [Related]
37. Emerging therapies in β-thalassemia: toward a new era in management.
Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
[TBL] [Abstract][Full Text] [Related]
38. Thalassemia Major: Transplantation or Transfusion and Chelation.
Mohamed SY
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):290-298. PubMed ID: 28651066
[TBL] [Abstract][Full Text] [Related]
39. Health state utilities associated with treatment for transfusion-dependent β-thalassemia.
Matza LS; Paramore LC; Stewart KD; Karn H; Jobanputra M; Dietz AC
Eur J Health Econ; 2020 Apr; 21(3):397-407. PubMed ID: 31828456
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.
Chuansumrit A; Sirachainan N; Kitpoka P; Kadegasem P; Songdej D; Sasanakul W; Wongwerawattanakoon P
Hemoglobin; 2019; 43(4-5):264-272. PubMed ID: 31760834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
